Business of the House

Debate between Lord Lansley and Lord Field of Birkenhead

Thursday 26th June 2014 Commons Chamber

[Mr Lansley]

My hon. Friend will—[Interruption.] Perhaps the hon. Member for Dunfermline and West Fife (Thomas Docherty) wants to reply to the questions. I have no doubt he does, but it is my responsibility, and it is Ministers’ responsibility to ensure the accuracy of their responses to Members. My hon. Friend may be aware that the Public Administration Committee is examining the issue of the accountability of public bodies and their responses to Members’ questions. Notwithstanding all that, it is important for NHS England to ensure that it provides my hon. Friend with accurate information. I will ensure, with the Department of Health, that that is the case.

[Mr Frank Field (Birkenhead) (Lab)]

I thank the Leader of the House for the statement about the Modern Slavery Bill. He is aware that there is substantial support on both sides of the House for the measure. Will he therefore guesstimate for us when it will complete its process here before going to the other place, even if this House tweaks it, hopefully, in a couple of important respects?

Life Sciences

Debate between Lord Lansley and Lord Field of Birkenhead

Monday 5th December 2011 Commons Chamber

[Mr Lansley]

I am grateful to my hon. Friend. He and I share a vigorous and vibrant life sciences sector, and I hope that the strategy that we have announced today will be taken up rapidly in our constituencies. He asks about the Academy of Medical Sciences. Back in the “Plan for Growth” in the Budget, we responded precisely to that point, and on 1 December, as a consequence of the positive response to what the academy said, I brought into effect the Health Research Authority to ensure that we simplify the process of approval for clinical trials. Through the National Institute for Health Research, as we said earlier in the year, we are seeking to arrive at a point where there is a maximum of 70 days for the first recruitment of patients to clinical trials, and that will get us into an internationally competitive position.

[Mr Frank Field (Birkenhead) (Lab)]

May I ask the Secretary of State a further question about the rights of people to opt out of the scheme? Will he extend the right of opt-out for those people who refuse to participate in the scheme to include a refusal of the advantages that come from sharing such information, which will be gained by the generosity of spirit of their fellow citizens who participate?

[Mr Lansley]

I understand the right hon. Gentleman’s point, but the ethical approach is for everyone to have access to the latest and best available treatments through the NHS. That is the principle that we apply, but we should be aware that, although we offer people the right to opt out, we have seen—for example, in relation to the general practice research database, where patients have the equivalent right to opt out, and in two pilots conducted on the proposals that we have announced—that the rate of opt out is 0.1%.